CRISPR-Cas technologies have transformed what is possible in gene editing. From genetic disease research and cell engineering through to next-generation therapeutics, the ability to make precise genetic modifications has accelerated innovation across the life sciences.
The landmark approval of CASGEVY® (exagamglogene autotemcel), the first CRISPR/Cas9-based therapy approved by the U.S. FDA for sickle cell disease, has accelerated the transition of genome editing from the laboratory into clinical practice.[1],[2] While this milestone validated the potential of gene editing, it also highlighted the importance of effective delivery technologies in translating genetic medicines into real-world therapies.
Yet despite the rapid advancement of gene-editing technologies, one challenge remains central to many development programmes: Delivery. A gene-editing payload can only be effective if it reaches its target safely, efficiently and consistently.[3] As a result, delivery has become one of the most important areas of focus for scientists seeking to translate promising CRISPR-based approaches into reproducible outcomes.
The success of any CRISPR program depends on far more than the editing mechanism itself.
Cas nucleases, guide RNAs (gRNAs), messenger RNA (mRNA) and other editing components must first be delivered into target cells and reach the appropriate intracellular compartment before any editing can occur. Every step of this journey introduces potential challenges.
Key considerations for drug delivery include:
The answers to these questions directly influence editing efficiency, safety and overall development success. This is why delivery has become such an important area of innovation within gene-editing research.
Unlike traditional small-molecule drugs, CRISPR payloads are comparatively large, complex and fragile biological materials.
Nucleic acids such as DNA and RNA can degrade rapidly within biological environments. In addition, cell membranes naturally act as protective barriers, making intracellular delivery particularly challenging.
As a result, delivery systems must fulfil two critical roles:
Without effective delivery, even highly sophisticated editing systems may fail to achieve their intended biological effect.
While viral vectors remain an important tool, non-viral delivery systems are attracting increasing attention. Among these, lipid nanoparticles (LNPs) have emerged as one of the most promising approaches, capable of carrying a variety of payload formats including mRNA, DNA and ribonucleoprotein (RNP) complexes.
Importantly, interest in LNPs extends beyond delivery alone. Their versatility allows scientists to optimize and refine formulations throughout development, creating opportunities to improve performance, targeting, and reproducibility.
Lipid nanoparticles have already demonstrated their value within RNA therapeutics and vaccines, helping establish LNPs as a clinically validated delivery technology.[5],[6] As interest in CRISPR-based therapies grows, LNPs are increasingly being investigated because they can help protect nucleic acid payloads while supporting efficient intracellular delivery.
However, once an LNP strategy has been selected, the challenge shifts from delivery to formulation development. Each lipid composition typically requires optimization of several process parameters, including:
Even relatively small changes in these variables can influence critical nanoparticle characteristics such as particle size, Polydispersity Index (PDI), and Encapsulation Efficiency (EE%). In turn, these characteristics can significantly impact biological performance and delivery outcomes.[7],[8]
Successful CRISPR delivery therefore depends not only on selecting the right drug delivery platform, but also on identifying the right formulation.
In practice, development teams are rarely trying to produce a single nanoparticle formulation.
Instead, they are searching for the formulation that provides the optimal balance between:
Recent advances such as Selective Organ Targeting (SORT) nanoparticles underscore the importance of formulation science.[4]
Researchers have demonstrated that relatively small changes in lipid composition can dramatically alter nanoparticle biodistribution, enabling delivery beyond the liver and into tissues such as the lungs and spleen. These findings demonstrate that formulation is about far more than particle size or encapsulation efficiency. It is also about controlling where therapies travel within the body and how effectively they perform once they arrive.
As a result, successful CRISPR-LNP development often requires extensive screening and optimization. Generating robust data across multiple formulation conditions is increasingly essential for understanding how formulation variables influence both nanoparticle characteristics and biological outcomes.
As formulation strategies become more sophisticated, low-volume screening is becoming increasingly valuable. The ability to evaluate more conditions using smaller quantities of valuable materials allows development teams to explore a broader formulation space whilst conserving expensive payloads.
This is one reason the TAMARA Nanoparticle Formulation System has gained attention within nanoparticle R&D. Developed by Inside Therapeutics and distributed by Microfluidics in the USA and Canada, TAMARA supports formulation volumes ranging from 200 µL through to 30 mL on a single platform, providing continuity from formulation screening through to in vivo-scale studies.
For development programs where every experiment generates valuable insight, low-volume screening creates opportunities to evaluate more conditions and make more informed development decisions.
Generating data is important. Generating reliable data is essential. If differences in performance arise from formulation variability rather than formulation design, optimization becomes more difficult, more time consuming, and ultimately less informative. This is why reproducibility remains an important consideration in CRISPR-LNP development.
Microfluidic technologies are widely regarded as the gold standard for LNP production because they provide highly controlled mixing under laminar flow conditions.[8] This level of process control enables formulation variables to be assessed with greater confidence whilst reducing the risk of introducing variability into development studies.
Reliable formulation workflows support:
Although every program has different objectives, several parameters are consistently monitored during nanoparticle optimization.
Efficient encapsulation helps maximize the use of valuable payloads while reducing material waste. TAMARA has demonstrated RNA encapsulation efficiencies of up to 98%, supporting efficient use of nucleic acid materials throughout formulation studies.
Particle size and size distribution are important considerations when evaluating delivery and transfection performance. Using controlled microfluidic mixing, TAMARA can produce RNA-LNP formulations with PDI values below 0.2, supporting highly uniform nanoparticle populations.
Optimization often requires screening multiple formulation conditions before selecting a candidate. With processing and cleaning times of less than two minutes per run, TAMARA supports rapid formulation development workflows.
Many CRISPR payloads are expensive and available only in limited quantities. Formulation approaches that minimize material losses and maximize utilization can provide significant advantages, particularly during early-stage development.
A common challenge in nanoparticle development is maintaining continuity throughout the R&D process. Formulations identified during screening frequently need to progress into larger-scale studies before additional development decisions can be made.
TAMARA addresses this challenge by supporting formulation volumes from 200 µL to 30 mL on a single system, helping maintain consistency across multiple stages of development. This continuity can simplify workflow progression while supporting reproducibility from screening through to in vivo evaluation.
As CRISPR technologies continue to evolve, delivery will remain a key factor influencing development success. Lipid nanoparticles are increasingly being explored because they offer flexibility, scalability, and compatibility with multiple payload formats. However, successful delivery depends on more than simply selecting an LNP strategy. It depends on the ability to develop, optimize, and reproduce formulations with confidence. As increasingly sophisticated LNP designs emerge, the need for efficient formulation development tools will continue to grow.
The TAMARA Nanoparticle Formulation System was developed to address this challenge through reproducible microfluidic mixing, rapid low-volume screening, and scale-up, to volumes suitable for in vivo testing on a single platform. By enabling efficient formulation development while maintaining confidence in reproducibility, TAMARA helps support the next generation of CRISPR-LNP research.
Contact us to arrange a discussion with a specialist and explore how TAMARA can support your formulation development workflow.